AC Immune has been granted a patent for a novel compound (formula I) that can be used to treat or prevent disorders associated with Tau protein aggregates, including Alzheimer’s disease. GlobalData’s report on AC Immune gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights AC Immune SA - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AC Immune, neuro-degenerative receptor binding drug compositions was a key innovation area identified from patents. AC Immune's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of disorders associated with tau protein aggregates

Source: United States Patent and Trademark Office (USPTO). Credit: AC Immune SA

A recently granted patent (Publication Number: US11684625B2) discloses a compound of formula (I) and its use in various methods related to decreasing Tau aggregation and preventing the formation of Tau aggregates. Tau aggregation is a process associated with neurodegenerative diseases such as Alzheimer's disease.

The patent claims cover a compound of formula (I) and its use in pharmaceutical compositions. The compound can be administered to a subject in need to decrease Tau aggregation, prevent the formation of Tau aggregates, or interfere intracellularly with Tau aggregates. These methods involve administering an effective amount of the compound to achieve the desired therapeutic effect.

Additionally, the patent claims cover mixtures comprising the compound of formula (I) and at least one further biologically active compound. The further biologically active compound can be a therapeutic agent used in the treatment of amyloidosis or a variety of other compounds with different mechanisms of action. The mixture may also include a pharmaceutically acceptable carrier, diluent, or excipient. The compound and/or the further biologically active compound should be present in a therapeutically effective amount.

The patent provides a valuable contribution to the field of neurodegenerative disease research by disclosing a compound and its use in various methods related to Tau aggregation. The compound and its mixtures with other biologically active compounds have the potential to be developed into pharmaceutical compositions for the treatment of neurodegenerative diseases associated with Tau aggregation, such as Alzheimer's disease. Further research and development based on this patent may lead to the discovery of new therapeutic options for patients in need.

To know more about GlobalData’s detailed insights on AC Immune, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies